Pursuant to Reg 33 read with Part A of Schedule III of SEBI (LODR) Regulation, 2015, we hereby submitting the following: 1. Standalone Audited Financial Results for the Quarter ended ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rekvina Laboratories Ltd reported standalone audited financial results for FY2026 (year ended March 31, 2026). Revenue from operations grew to Rs. 126.54 lakhs from Rs. 118.16 lakhs in FY2025, a modest ~7% increase. The company swung from a net loss of Rs. 6.05 lakhs in FY2025 to a net profit of Rs. 25.47 lakhs in FY2026. Total comprehensive income also turned positive at Rs. 25.24 lakhs versus a loss of Rs. 6.05 lakhs previously. The statutory auditor (Y. M. Shah & Co.) issued an unmodified (clean) opinion on the annual financial results. The board also approved a 100% equity acquisition of Narmiani Laboratories Ltd for Rs. 462.77 lakhs via share exchange, and a share subscription agreement for Rs. 46 lakhs. No dividend was recommended.
The company returned to profitability after a loss-making FY2025, which is a positive signal. However, revenue growth is modest at ~7% and the auditor has not raised concerns. The significant acquisition of Narmiani Laboratories and the share subscription agreement indicate potential major corporate restructuring ahead.